INRLF

VLA1553

Chikungunya

Phase 3 (Top-line Data)

Exp Date

Q1 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: VLA1553 for Chikungunya - Phase 3 Top-line Data

  • Phase 3 - ClinicalTrial.gov (NCT04546724) Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults


  • Phase 1 - ClinicalTrial.gov (NCT03382964) Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 3 Top-line Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION / RATIONALE

  • VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate against chikungunya (learn more HERE). 

Updated by HC

VLA, VLA1553, Chikungunya, vaccine, 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon